Sionna Therapeutics (SION) Share-based Compensation (2024 - 2026)

Sionna Therapeutics has disclosed Share-based Compensation across 3 years of filings, most recently posting $6.6 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $6.6 million, up 212.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.5 million (up 220.56% YoY), and the FY2025 annual result was $12.1 million, up 225.4% from the prior year.
• Share-based Compensation came in at $6.6 million for Q1 2026 at Sionna Therapeutics, up from $3.8 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $6.6 million in Q1 2026 to a low of $647000.0 in Q1 2024.
• The 3-year median for Share-based Compensation is $2.1 million (2025), against an average of $2.5 million.
• Peak annual rise in Share-based Compensation reached 259.59% in 2025, while the deepest fall reached 192.48% in 2025.
• Sionna Therapeutics' Share-based Compensation stood at $1.1 million in 2024, then surged by 259.59% to $3.8 million in 2025, then surged by 71.28% to $6.6 million in 2026.
• The last three Share-based Compensation figures came in at $6.6 million (Q1 2026), $3.8 million (Q4 2025), and $3.3 million (Q3 2025), per Business Quant data.